Dyadic International Inc.

DYAI

Healthcare Biotechnology

Dyadic International Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 million, down 11.6% from fiscal 2024.

Revenue
−61.4%
EPS
n/m
Free cash flow
n/m
Total debt
+0.80%

Quarter to September 2026, against a year earlier

0.33 0.02 −5.71%
Market cap
$14.0M
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
2/9
ROIC
0.00%
Net debt / EBITDA
0.5×
Payout ratio
—

Ratios over time FY16 to FY25

Returns on capital

ROIC was 0.0% in FY25, against a low of -380.1% in FY18.

ROEROIC
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
ROE−12.1%−4.0%−12.3%−21.2%−29.0%−55.8%−66.0%−80.1%−139.2%−397.8%
ROIC26.7%20.7%−380.1%−353.4%0.0%0.0%0.0%0.0%0.0%0.0%

Debt

Net debt is 0.49× a year’s EBITDA. Debt is 4.08× equity.

Debt / equityNet debt / EBITDA
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Debt / equity0.0×0.0×0.0×0.0×0.0×0.0×0.0×0.0×2.0×4.1×
Net debt / EBITDA−94.9×7.6×6.0×3.8×3.0×1.4×1.2×0.9×0.7×0.5×

Cash cycle, in days

Customers pay in 133 days and suppliers are paid in 134. Suppliers fund 1 days of working capital.

Cash cycleDays to pay suppliersDays to be paid
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Cash cycle4688720611−167−234−171−61−120−1
Days to pay suppliers197279110236260291219121147134
Days to be paid6663663162479357486027133

Per share, from FY16

Since FY16, per share: revenue has grown 21.7% a year; book value has fallen 33.9% a year.

RevenueBook value
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Revenue1.0×1.6×2.9×3.8×3.6×5.3×6.4×6.2×7.4×5.8×
Book value1.0×1.1×1.0×0.8×0.7×0.4×0.2×0.1×0.1×0.0×
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Piotroski F-Score
2 4 4 4 4 3 4 — — —
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
(12.37) (8.73) (3.89) (0.80) 20.64 52.26 51.62 36.48 31.30 —
P/S ratio
9.92 14.68 15.80 13.36 52.35 92.26 83.21 40.39 63.08 0.00
Altman Z″-Score (non-manufacturers)
(31.25) (27.03) (31.29) (12.77) (2.08) 16.78 24.41 55.15 71.82 —
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Beneish M-Score
1.00 (4.48) (2.54) (3.27) (3.36) (3.54) (2.80) (2.39) — —
P/Operating CF
(17.32) (73.67) (49.59) (23.27) (47.75) (114.84) (99.85) (42.57) (28.31) 0.00
P/B ratio
24.88 20.77 7.79 3.53 6.84 5.20 3.90 1.23 0.96 0.00
EV/Sales
8.78 13.45 13.33 9.04 43.92 74.10 62.85 8.57 0.25 (8.35)
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.25 0.00
EV/FCF
(4.67) (11.51) (5.65) (3.23) (9.27) (17.76) (17.93) (2.46) (0.15) 0.00
Current Ratio
2.68 4.01 3.58 5.48 8.22 18.32 22.44 50.32 64.53 57.05
Net Debt/EBITDA
0.49 0.73 0.88 1.25 1.41 3.00 3.77 5.96 7.57 (94.95)
Debt/Equity
4.08 2.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE
(397.80%) (139.16%) (80.11%) (66.05%) (55.81%) (29.00%) (21.22%) (12.32%) (3.97%) (12.14%)
ROA
(74.11%) (64.01%) (61.97%) (55.61%) (50.89%) (27.62%) (20.58%) (12.10%) (8.42%) 0.00%
ROIC
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% (353.37%) (380.11%) 20.70% 26.74%
Return on Tangible Assets
(118.60%) (78.72%) (116.85%) (88.72%) (70.83%) (33.12%) (24.40%) (13.58%) (4.37%) (6.37%)
Average Days of Receivables
132.92 27.29 59.96 48.37 56.52 92.60 247.19 315.53 366.20 665.62
Earnings Yield
(26.60%) (11.25%) (15.09%) (24.64%) (10.39%) (6.34%) (5.98%) (10.91%) (5.00%) (5.70%)
Free Cash Flow Yield
(18.96%) (7.96%) (14.93%) (20.94%) (9.05%) (4.52%) (4.21%) (8.64%) (2.72%) 0.00%
Free Cash Flow per Share
(0.17) (0.14) (0.23) (0.28) (0.41) (0.24) (0.21) (0.16) (0.06) (0.17)
Book value per Share
0.04 0.08 0.20 0.39 0.66 1.04 1.33 1.53 1.73 1.58
Free Cash Flow
(5.70) (3.97) (6.73) (8.08) (11.28) (6.57) (5.78) (4.41) (1.69) (6.04)
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.25 0.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 13 Nov 2026